VETIGENICS
Vetigenics creates novel immunotherapies to treat cancer and other chronic conditions in dogs without the debilitating side effects. Our fully canine phage display platform, enables rapid isolation of unique antibody fragments (scFvs) or CANIBODIES™ to any antigen based binding affinity, functionality and developability. CANIBODIES™ are entirely generated from naïve, canine germline genes, don't require costly, time-consuming caninization and can be readily engineered into mAbs, BiTEs or CAR-T therapies. As a result, our therapies are designed for precision efficacy and lack of immunogenicity, not possible with other discovery technologies. Vetigenics is advancing three internally developed antibody products into the clinic with our 1st in dog studies starting during 1Q21
VETIGENICS
Social Links:
Industry:
Biotechnology Pet
Founded:
2017-09-17
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.vetigenics.com
Total Employee:
1+
Status:
Active
Contact:
2678752283
Email Addresses:
[email protected]
Total Funding:
550 K USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Google Maps Content Delivery Network
Similar Organizations
BarkBox
Barkbox is a monthly subscription service platform that provides dog products.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Sesen Bio, Inc.
Sesen Bio, Inc. is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.
FlexSea
FlexSea develops novel biomaterials derived from renewable marine resources to replace current primary plastic packaging.
Front of the Pack
Pure and simple dog supplements, delivered.
HEY HOLY
We’re transforming pet care — with a breed-specific health concept instead of one-size-fits-all, with longevity at its core
LTZ Therapeutics
LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need.
TômTex Co
TomTex recycles agriculture waste and creates a sustainable, accessible, and practical alternatives to currently commercial materials.
UNCAGED Innovations
UNCAGED Innovations is a biomaterials company combining the power of nature and technology to reimagine leather.
Xencor
Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.
Current Employees Featured
Founder
Investors List
Newchip Accelerator
Newchip Accelerator investment in Pre Seed Round - Vetigenics
Official Site Inspections
http://www.vetigenics.com
- Host name: web2.axxiem.com
- IP address: 34.230.198.252
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Vetigenics"
Home - Vetigenics
Vetigenics is dedicated to developing innovative antibody therapies that enhance the quality of life for pets living with chronic diseases. Vetigenics’ proprietary CANIBODYâ„¢ Platform is an …See details»
Company & Leadership - Vetigenics
Vetigenics is a pet health biopharma company devoted to enabling pets to live their best lives. Vetigenics was established in 2017 to address the growing need within the National Cancer Institute (NCI) to generate fully canine research …See details»
Vetigenics - Crunchbase Company Profile & Funding
Vetigenics creates novel immunotherapies to treat cancer and other chronic conditions in dogs without the debilitating side effects. Our fully canine phage display platform, enables rapid …See details»
Leadership Team - Vetigenics
Founder of Vetigenics, and globally recognized for groundbreaking contributions in Antibody Discovery. Dr. Siegel is Co-Founder of Vetigenics and serves as Co-Chair of its Scientific Advisory Board.See details»
Vetigenics - LinkedIn
Vetigenics is at the forefront of developing targeted antibody therapies for pets, addressing the critical need for more accessible and effective treatments for cancer and other chronic diseases.See details»
Vetigenics’ Treats its First Canine Cancer Patient
In November 2023, Vetigenics announced that the first client-owned canine patient with oral melanoma received the first dose of the company’s anti-CTLA4 monoclonal antibody (VGS-001) in a clinical trial.See details»
Vetigenics - Products, Competitors, Financials, Employees, …
Vetigenics operates as a biotechnology company focusing on developing antibody-based therapies for pets with cancer and other chronic diseases. The company offers a range of …See details»
Vetigenics Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Vetigenics. Use the PitchBook Platform to explore the full profile.See details»
Could pharma’s blockbuster immunotherapies work in dogs?
Jul 9, 2024 · Vetigenics is trying to change that by developing targeted antibody therapies for pets that are more affordable and can be administered by veterinary generalists. As investments in …See details»
Vetigenics’ Canibody platform attracting more potential …
In late 2022, Vetigenics secured its second discovery partner for its companion animal therapeutic antibody platform. With an existing agreement with Merck Animal Health, the company now …See details»
Vetigenics Company Profile - Office Locations, Competitors, …
Vetigenics is a pet health biopharmaceutical company. It offers CANIBODY, a phage display library that contains bacteriophage particles used to generate antibodies. Vetigenics has 5 …See details»
Vetigenics - Penn Center for Innovation
Using novel phage-display techniques to develop reagents and therapeutics for veterinary medicine. Founded by: Nicola Mason. Vetigenics website. Participates in PCI Ventures …See details»
Vetigenics Receives Startup Of The Year Award From Penn Center …
PHILADELPHIA, Dec. 3, 2021 /PRNewswire/ -- Vetigenics, a privately held animal health biotechnology company, has been chosen Startup of the Year 2021 by the University of …See details»
Vetigenics Extends Merck Animal Health Collaboration - LinkedIn
Nov 2, 2021 · VETIGENICS is a privately held animal health biopharmaceutical company committed to improving canine health through the development of entirely canine, safe and …See details»
Vetigenics LLC Company Profile | Philadelphia, PA | Competitors ...
Find company research, competitor information, contact details & financial data for Vetigenics LLC of Philadelphia, PA. Get the latest business insights from Dun & Bradstreet.See details»
VETIGENICS Announces Discovery Collaboration With Merck …
Nov 2, 2021 · VETIGENICS is a privately held animal health biopharmaceutical company committed to improving canine health through the development of entirely canine, safe and …See details»
Vetigenics Announces Discovery Collaboration With Merck Animal …
PHILADELPHIA, Nov. 2, 2021 /PRNewswire/ — VETIGENICS, an animal health biotechnology company, today announced that it is extending its discovery collaboration with Merck Animal …See details»
Vetigenics - Overview, News & Similar companies | ZoomInfo.com
Nov 8, 2022 · Vetigenics is a privately held animal health biopharmaceutical company committed to improving canine health through the development of entirely canine, safe and effective …See details»
VETIGENICS ANNOUNCES PUBLICATION OF COMPREHENSIVE …
PHILADELPHIA, Jan. 5, 2022 /PRNewswire/ -- Vetigenics, an animal health biotechnology company, has announced preclinical data that paves the way for clinical evaluation of the first …See details»
VETIGENICS ANNOUNCES SECOND DISCOVERY COLLABORATION …
Nov 8, 2022 · Vetigenics is a privately held animal health biopharmaceutical company committed to improving the health and well-being of companion animals through the discovery and …See details»